Cutaneous malignant melanoma: Update on diagnostic and prognostic biomarkers

American Journal of Dermatopathology

Volumn 36, Issue 5, 2014, Pages 363-379

  Abbas, Ossama ^a   Miller, Daniel D ^b   Bhawan, Jag ^b  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

biomarkers; malignant melanoma

Indexed keywords

B RAF KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; GEMININ; GENOMIC DNA; HISTONE H3; KI 67 ANTIGEN; KPNA2 PROTEIN; MINICHROMOSOME MAINTENANCE PROTEIN 3; MINICHROMOSOME MAINTENANCE PROTEIN 4; MINICHROMOSOME MAINTENANCE PROTEIN 6; PHOSPHOHISTONE H3; PROTEIN P16; TUMOR MARKER; UNCLASSIFIED DRUG;

ALLELIC IMBALANCE; ARTICLE; BLUE NEVUS; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CLINICAL INDICATOR; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; CPG ISLAND; CUTANEOUS MELANOMA; DESMOPLASTIC MELANOMA; DISEASE FREE SURVIVAL; DNA METHYLATION; DYSPLASTIC NEVUS; EPIGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE MUTATION; HISTONE MODIFICATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; JUVENILE MELANOMA; MELANOCYTE; MELANOCYTIC NEVUS; METASTASIS FREE SURVIVAL; MICROSATELLITE MARKER; MITOSIS RATE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; MULTIPLEX POLYMERASE CHAIN REACTION; NUCLEOTIDE SEQUENCE; ONCOGENE H RAS; ONCOGENE N RAS; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SKIN ULCER; SPITZ NEVI; UPREGULATION; UVEA MELANOMA; GENETICS; MELANOMA; MORTALITY; PROGNOSIS;

HUMANS; MELANOMA; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84900835127     PISSN: 01931091     EISSN: 15330311     Source Type: Journal    
DOI: 10.1097/DAD.0b013e31828a2ec5     Document Type: Article

References (153)

1. Elwood JM, Koh HK. Etiology, epidemiology, risk factors, and public health issues of melanoma. Curr Opin Oncol. 1994;6:179-187.
2. Leiter U, Garbe C. Epidemiology of melanoma and nonmelanoma skin cancer-The role of sunlight. Adv Exp Med Biol. 2008;624:89-103.
3. Magro CM, Crowson AN, Mihm MC. Unusual variants of malignant melanoma. Mod Pathol. 2006;19:S41-S70.
4. Barnhill RL, Mihm MC Jr. The histopathology of cutaneous malignant melanoma. Semin Diagn Pathol. 1993;10:47-75.
5. Mangini J, Li N, Bhawan J. Immunohistochemical markers of melanocytic lesions: a review of their diagnostic usefulness. Am J Dermatopathol. 2002;24:270-281.
6. Ohsie SJ, Sarantopoulos GP, Cochran AJ, et al. Immunohistochemical characteristics of melanoma. J Cutan Pathol. 2008;35:433-444.
7. Gould Rothberg BE, Bracken MB, Rimm DL. Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and metaanalysis. J Natl Cancer Inst. 2009;101:452-474.
8. Carlson JA, Ross JS, Slominski A, et al. Molecular diagnostics in melanoma. J Am Acad Dermatol. 2005;52:743-775.
9. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19: 3622-3634.
10. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311-322.
11. Li LXL, Crotty KA, McCarthy SW, et al. A zonal comparison of MIB1- Ki67 immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol. 2000;22:489-495.
12. Kanter-Lewensohn L, Hedblad MA, Wejde J, et al. Immunohistochemical markers for distinguishing Spitz nevi from malignant melanomas. Mod Pathol. 1997;10:917-920.
13. Chorny JA, Barr RJ, Kyshtoobayeva A, et al. Ki-67 and p53 expression in minimal deviation melanomas as compared with other nevomelanocytic lesions. Mod Pathol. 2003;16:525-529.
14. Stefanski C, Stefanski K, Antoniou C, et al. G1 cell cycle regulators in congenital melanocytic nevi. Comparison with acquired nevi and melanomas. J Cutan Pathol. 2008;35:799-808.
15. Ostmeier H, Fuchs B, Otto F, et al. Prognostic immunohistochemical markers of primary human melanomas. Br J Dermatol. 2001;145:203-209.
16. Sparrow LE, English DR, Taran JM, et al. Prognostic significance of MIB-1 proliferative activity in thin melanomas and immunohistochemical analysis of MIB-1 proliferative activity in melanocytic tumors. Am J Dermatopathol. 1998;20:12-16.
17. Frahm SO, Schubert C, Parwaresch R, et al. High proliferative activity may predict early metastasis of thin melanomas. Hum Pathol. 2001;32: 1376-1381.
18. Hazan C, Melzer K, Panageas KS, et al. Evaluation of the proliferation marker MIB-1 in the prognosis of cutaneous malignant melanoma. Cancer. 2002;95:634-640.
19. Casper DJ, Ross KI, Messina JL, et al. Use of anti-phosphohistone H3 immunohistochemistry to determine mitotic rate in thin melanoma. Am J Dermatopathol. 2010;32:650-654.
20. Ribalta T, McCutcheon IE, Aldape KD, et al. The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria. Am J Surg Pathol. 2004;28:1532-1536.
21. Colman H, Giannini C, Huang L, et al. Assessment and prognostic significance of mitotic index using the mitosis marker phosphohistone H3 in low and intermediate-grade infiltrating astrocytomas. Am J Surg Pathol. 2006;30:657-664.
22. Ikenberg K, Pfaltz M, Rakozy C, et al. Immunohistochemical dual staining as an adjunct in assessment of mitotic activity in melanoma. J Cutan Pathol. 2012;39:324-330.
23. Nielsen PS, Riber-Hansen R, Jensen TO, Schmidt H, Steiniche T. Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma. Mod Pathol. 2013;26(3):404-414.
24. Talve L, Sauroja I, Collan Y, et al. Loss of expression of the p16 INK4/ CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage. Int J Cancer. 1997;74:255-259.
25. Hilliard NJ, Krahl D, Sellhayer K. p16 Expression differentiates between desmoplastic Spitz nevus and desmoplastic melanoma. J Cutan Pathol. 2009;36:753-759.
26. Al Dhaybi R, Agoumi M, Gagne I, et al. p16 Expression: a marker of differentiation between childhood malignant melanomas and Spitz nevi. J Am Acad Dermatol. 2011;65:357-363.
27. Mason A, Wititsuwannakul J, Klump VR, Lott J, Lazova R. Expression of p16 alone does not differentiate between Spitz nevi and Spitzoid melanoma. J Cutan Pathol. 2012;39(12):1064-1072.
28. Alonso SR, Ortiz P, Pollan M, et al. Progression in cutaneous malignant melanoma is associated with distinct expression profiles. Am J Pathol. 2004;164:193-203.
29. Slipicevic A, Holm R, Nguyen MT, et al. Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome. Am J Clin Pathol. 2005;124:528-536.
30. Flrenes VA, Mlandsmo GM, Holm R. Expression of activated TrkA protein in melanocytic tumors: relationship to cell proliferation and clinical outcome. Am J Clin Pathol. 2004;122:412-420.
31. Zhuang L, Lee CS, Scolyer RA, et al. Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Mod Pathol. 2007;20:416-426.
32. Kuzbicki L, Aladowicz E, Chwirot B. Cyclin dependent kinase 2 expression in human melanomas and benign melanocytic skin lesions. Melanoma Res. 2006;16:435-444.
33. Tran TA, Ross JS, Carlson JA, et al. Mitotic cyclins and cyclin dependent kinases in melanocytic lesions. Hum Pathol. 1998;29:1085-1090.
34. Korabiowska M, Betke H, Kellner S, et al. Differential expression of growth arrest, DNA damage genes and tumour suppressor gene p53 in naevi and malignant melanomas. Anticancer Res. 1997;17: 3697-3700.
35. Polsky D, Melzer K, Hazan C, et al. HDM2 protein overexpression and prognosis in primary malignant melanoma. J Natl Cancer Inst. 2002;94: 1803-1806.
36. Karim RZ, Li W, Sanki A, et al. Reduced p16 and increased cyclin D1 and pRb expression are correlated with progression in cutaneous melanocytic tumors. Int J Surg Pathol. 2009;17:361-367.
37. Li Q, Murphy M, Ross J, et al. Skp2 and p27kip1 expression in melanocytic nevi and melanoma: an inverse relationship. J Cutan Pathol. 2004;31:633-642.
38. Luftl M, Schuler G, Jungbluth AA. Melanoma or not? Cancer testis antigens may help. Br J Dermatol. 2004;151:1213-1218.
39. van den Oord JJ. Expression of CD26/dipeptidyl peptidase IV in benign and malignant pigment-cell lesions of the skin. Br J Dermatol. 1998; 138:615-621.
40. van den Oord JJ, Maes A, Stas M, et al. CD40 is a prognostic marker in primary cutaneous malignant melanoma. Am J Pathol. 1996;149: 1953-1961.
41. Bullani RR, Huard B, Viard-Leveugle I, et al. Selective expression of FLIP in malignant melanocytic skin lesions. J Invest Dermatol. 2001; 117:360-364.
42. Niemann TH, Argenyi ZB. Immunohistochemical study of Spitz nevi and malignant melanoma with use of antibody to proliferating cell nuclear antigen. Am J Dermatopathol. 1993;15:441-445.
43. Ribe A, McNutt NS. S100A6 protein expression is different in Spitz nevi and melanomas. Mod Pathol. 2003;16:505-511.
44. Bastian BC, Olshen AB, LeBoit PE, et al. Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol. 2003; 163:1765-1770.
45. Bauer J, Bastian BC. Distinguishing melanocytic nevi from melanoma by DNA copy number changes: comparative genomic hybridization as a research and diagnostic tool. Dermatol Ther. 2006;19:40-49.
46. Healy E, Belgaid CE, Takata M, et al. Allelotypes of primary cutaneous melanoma and benign melanocytic nevi. Cancer Res. 1996;56:589-593.
47. Onken MD, Worley LA, Person E, et al. Loss of heterozygosity of chromosome 3 detected with single nucleotide polymorphisms is superior to monosomy 3 for predicting metastasis in uveal melanoma. Clin Cancer Res. 2007;13:2923-2927.
48. White JS, McLean IW, Becker RL, et al. Correlation of comparative genomic hybridization results of 100 archival uveal melanomas with patient survival. Cancer Genet Cytogenet. 2006;170:29-39.
49. Trolet J, Hupe P, Huon I, et al. Genomic profiling and identification of high-risk uveal melanoma by array CGH analysis of primary tumors and liver metastases. Invest Ophthalmol Vis Sci. 2009;50; 2572-2580.
50. Schouten JP, McElgunn CJ, Waaijer R, et al. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002;30:e57.
51. van DijkMC, Rombout PD, Boots-Sprenger SH, et al. Multiplex ligationdependent probe amplification for the detection of chromosomal gains and losses in formalin-fixed tissue. Diagn Mol Pathol. 2005;14:9-16.
52. Takata M, Suzuki T, Ansai S, et al. Genome profiling of melanocytic tumors using multiplex ligation dependent probe amplification (MLPA): its usefulness as an adjunctive diagnostic tool for melanocytic tumors. J Dermatol Sci. 2005;40:51-57.
53. Gerami P, Jewell SS, Morrison LE, et al. Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Am J Surg Pathol. 2009;33:1146-1156.
54. Pouryazdanparast P, Haghighat Z, Beilfuss BA, et al. Melanocytic nevi with an atypical epithelioid cell component: clinical, histopathologic, and fluorescence in situ hybridization findings. Am J Surg Pathol. 2011; 35:1405-1411.
55. Gerami P, Beilfuss B, Haghighat Z, et al. Fluorescence in situ hybridization as an ancillary method for the distinction of desmoplastic melanomas from sclerosing melanocytic nevi. J Cutan Pathol. 2011;38: 329-334.
56. Pouryazdanparast P, Newman M, Mafee M, et al. Distinguishing epithelioid blue nevus from blue nevus-like cutaneous melanoma metastasis using fluorescence in situ hybridization. Am J Surg Pathol. 2009;33: 1396-1400.
57. Dalton SR, Gerami P, Kolaitis NA, et al. Use of fluorescence in situ hybridization (FISH) to distinguish intranodal nevus from metastatic melanoma. Am J Surg Pathol. 2010;34:231-237.
58. Gammon B, Beilfuss B, Guitart J, et al. Fluorescence in situ hybridization for distinguishing cellular blue nevi from blue nevus-like melanoma. J Cutan Pathol. 2011;38:335-341.
59. Gammon B, Beilfuss B, Guitart J, et al. Enhanced detection of spitzoid melanomas using fluorescence in situ hybridization with 9p21 as an adjunctive probe. Am J Surg Pathol. 2012;36:81-88.
60. Gaiser T, Kutzner H, Palmedo G, et al. Classifying ambiguous melanocytic lesions with FISH and correlation with clinical long-Term follow up. Mod Pathol. 2010;23:413-419.
61. Gerami P, Li G, Pouryazdanparast P, et al. A highly specific and discriminatory FISH assay for distinguishing between benign and malignant melanocytic neoplasms. Am J Surg Pathol. 2012;36:808-817.
62. Takata M, Saida T. Genetic alterations in melanocytic tumors. J Dermatol Sci. 2006;43:1-10.
63. Da Forno PD, Fletcher A, Pringle JH, et al. Understanding spitzoid tumours: new insights from molecular pathology. Br J Dermatol. 2008;158:4-14.
64. Bastian BC, LeBoit PE, Pinkel D. Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. Am J Pathol. 2000;157:967-972.
65. Da Forno PD, Pringle JH, Fletcher A, et al. BRAF, NRAS and HRAS mutations in spitzoid tumours and their possible pathogenetic significance. Br J Dermatol. 2009;161:364-372.
66. Fullen DR, Poynter JN, Lowe L, et al. BRAF and NRAS mutations in spitzoid melanocytic lesions. Mod Pathol. 2006;19:1324-1332.
67. Emley A, Yang S, Wajapeyee N, et al. Oncogenic BRAF and the tumor suppressor IGFBP7 in the genesis of atypical spitzoid nevomelanocytic proliferations. J Cutan Pathol. 2010;37:344-349.
68. Gill M, Cohen J, Renwick N, et al. Genetic similarities between Spitz nevus and Spitzoid melanoma in children. Cancer. 2004;101:2636-2640.
69. Palmedo G, Hantschke M, Rutten A, et al. The T1796A mutation of the BRAF gene is absent in Spitz nevi. J Cutan Pathol. 2004;31:266-270.
70. Lee DA, Cohen JA, Twaddell WS, et al. Are all melanomas the same? Spitzoid melanoma is a distinct subtype of melanoma. Cancer. 2006; 106:907-913.
71. Takata M, Lin J, Takayanagi S, et al. Genetic and epigenetic alterations in the differential diagnosis of malignant melanoma and spitzoid lesion. Br J Dermatol. 2007;156:1287-1294.
72. van Dijk MC, Bernsen MR, Ruiter DJ. Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the differential diagnosis of Spitz nevus and spitzoid melanoma. Am J Surg Pathol. 2005;29:1145-1151.
73. Richards HW, Medrano EE. Epigenetic marks in melanoma. Pigment Cell Melanoma Res. 2009;22:14-29.
74. Nguyen T, Kuo C, Nicholl MB, et al. Downregulation of microRNA- 29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma, Epigenetics 2011;6:388-394.
75. Rothhammer T, Bosserhoff AK. Epigenetic events in malignant melanoma. Pigment Cell Res. 2007;20:92-111.
76. Howell PM Jr, Liu S, Ren S, et al. Epigenetics in human melanoma. Cancer Control. 2009;16:200-218.
77. Schinke C, Mo Y, Yu Y, et al. Aberrant DNA methylation in malignant melanoma. Melanoma Res. 2010;20:253-265.
78. Sigalotti L, Covre A, Fratta E, et al. Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies. J Transl Med. 2010;8:56.
79. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation, N Engl J Med. 2003;349:2042-2054.
80. Nygren AO, Ameziane N, Duarte HM, et al. Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res. 2005;33:e128.
81. Bonazzi VF, Stark MS, Hayward NK. MicroRNA regulation of melanoma progression, Melanoma Res. 2012;22;101-113.
82. Mueller DW, Rehli M, Bosserhoff AK. miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma. J Invest Dermatol. 2009;129:1740-1751.
83. Philippidou D, Schmitt M, Moser D, et al. Signatures of microRNAs and selected microRNA target genes in human melanoma. Cancer Res. 2010;70:4163-4173.
84. Roush S, Slack FJ. The let-7 family of microRNAs. Trends Cell Biol. 2008;18:505-516.
85. Schultz J, Lorenz P, Gross G, et al. MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res. 2008;18:549-557.
86. Kouzarides T. Chromatin modifications and their function. Cell. 2007; 128:693-705.
87. Fan T, Jiang S, Chung N, et al. EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/ CDKN1A expression. Mol Cancer Res. 2011;9:418-429.
88. Zhang XD, Gillespie SK, Borrow JM, et al. The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol Cancer Ther. 2004;3:425-435.
89. Haqq C, Nosrati M, Sudilovsky D, et al. The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A. 2005;102:6092-6097.
90. Kashani-Sabet M, Rangel J, Torabian S, et al. A multimarker assay to distinguish malignant melanomas from benign nevi. Proc Natl Acad Sci U S A. 2009;106:6268-6272.
91. Talantov D, Mazumder A, Yu JX, et al. Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res. 2005;11:7234-7242.
92. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27: 6199-6206.
93. Cochran AJ. A glimpse of future management of melanoma. Arch Dermatol. 2009;145:1176-1177.
94. Carlson JA, Ross JS, Slominski AJ. New techniques in dermatopathology that help to diagnose and prognosticate melanoma. Clin Dermatol. 2009;27:75-102.
95. Gimotty PA, Elder DE, Fraker DL, et al. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol. 2007;25:1129-1134.
96. Berger AJ, Davis DW, Tellez C, et al. Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction. Cancer Res. 2005;65: 11185-11192.
97. Karjalainen JM, Kellokoski JK, Eskelinen MJ, et al. Downregulation of transcription factor AP-2 predicts poor survival in stage I cutaneous malignant melanoma. J Clin Oncol. 1998;16:3584-3591.
98. Berger AJ, Kluger HM, Li N, et al. Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Res. 2003;63:8103-8107.
99. Rangel J, Torabian S, Shaikh L, et al. Prognostic significance of nuclear receptor coactivator-3 overexpression in primary cutaneous melanoma. J Clin Oncol. 2006;24:4565-4569.
100. Alonso SR, Tracey L, Ortiz P, et al. A high-Throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Res. 2007;67:3450-3460.
101. Divito KA, Berger AJ, Camp RL, et al. Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma. Cancer Res. 2004;64:8773-8777.
102. Piras F, Murtas D, Minerba L, et al. Nuclear survivin is associated with disease recurrence and poor survival in patients with cutaneous malignant melanoma. Histopathology. 2007;50:835-842.
103. Thies A, Moll I, Berger J, et al. CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J Clin Oncol. 2002;20:2530-2536.
104. Scala S, Ottaiano A, Ascierto PA, et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res. 2005;11:1835-1841.
105. Karjalainen JM, Tammi RH, Tammi MI, et al. Reduced level of CD44 and hyaluronan associated with unfavorable prognosis in clinical stage I cutaneous melanoma. Am J Pathol. 2000;157:957-965.
106. Pacifico MD, Grover R, Richman PI, et al. Development of a tissue array for primary melanoma with long-Term follow-up: discovering melanoma cell adhesion molecule as an important prognostic marker. Plast Reconstr Surg. 2005;115:367-375.
107. Pearl RA, Pacifico MD, Richman PI, et al. Stratification of patients by melanoma cell adhesion molecule (MCAM) expression on the basis of risk: implications for sentinel lymph node biopsy. J Plast Reconstr Aesthet Surg. 2008;61:265-271.
108. Thies A, Schachner M, Moll I, et al. Overexpression of the cell adhesion molecule L1 is associated with metastasis in cutaneous malignant melanoma. Eur J Cancer. 2002;38:1708-1716.
109. Vaisanen AH, Kallioinen M, Turpeenniemi-Hujanen T. Comparison of the prognostic value of matrix metalloproteinases 2 and 9 in cutaneous melanoma. Hum Pathol. 2008;39:377-385.
110. Vaisanen A, Kallioinen M, Taskinen PJ, et al. Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J Pathol. 1998;186:51-58.
111. Rangel J, Nosrati M, Torabian S, et al. Osteopontin as a molecular prognostic marker for melanoma. Cancer. 2008;112:144-150.
112. Ilmonen S, Jahkola T, Turunen JP, et al. Tenascin-C in primary malignant melanoma of the skin. Histopathology. 2004;45:405-411.
113. Ferrier CM, Suciu S, van Geloof WL, et al. High tPA expression in primary melanoma of the limb correlates with good prognosis. Br J Cancer. 2000;83:1351-1359.
114. Niezabitowski A, Czajecki K, Rys J, et al. Prognostic evaluation of cutaneous malignant melanoma: a clinicopathologic and immunohistochemical study. J Surg Oncol. 1999;70:150-160.
115. Ekmekcioglu S, Ellerhorst JA, Prieto VG, et al. Tumor iNOS predicts poor survival for stage III melanoma patients. Int J Cancer. 2006;119: 861-866.
116. Straume O, Sviland L, Akslen LA. Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res. 2000;6:1845-1853.
117. Chen G, Cheng Y, Zhang Z, et al. Prognostic significance of cytoplasmic p27 expression in human melanoma. Cancer Epidemiol Biomark Prev. 2011;20:2212-2221.
118. Florenes VA, Maelandsmo GM, Faye R, et al. Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome. J Pathol. 2001;195:530-536.
119. Soltani MH, Pichardo R, Song Z, et al. Microtubule associated protein 2, a marker of neuronal differentiation, induces mitotic defects, inhibits growth of melanoma cells, and predicts metastatic potential of cutaneous melanoma. Am J Pathol. 2005;166:1841-1850.
120. Weinlich G, Eisendle K, Hassler E, et al. Metallothionein-overexpression as a highly significant prognostic factor in melanoma: a prospective study on 1270 patients. Br J Cancer. 2006;94:835-841.
121. Weinlich G, Topar G, Eisendle K, et al. Comparison of metallothioneinoverexpression with sentinel lymph node biopsy as prognostic factors in melanoma. J Eur Acad Dermatol Venereol. 2007;21:669-677.
122. Gimotty PA, Van Belle P, Elder DE, et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol. 2005;23:8048-8056.
123. Straume O, Akslen LA. Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin- A1/EphA2 on melanoma progression. Am J Pathol. 2002;160:1009-1019.
124. Giehl KA, Ngele U, Volkenandt M, et al. Protein expression of melanocyte growth factors (bFGF, SCF) and their receptors (FGFR-1, c-kit) in nevi and melanoma. J Cutan Pathol. 2007;34:7-14.
125. Bachmann IM, Straume O, Puntervoll HE, et al. Importance of P-cadherin, b-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clin Cancer Res. 2005;11:8606-8614.
126. Kageshita T, Hamby CV, Ishihara T, et al. Loss of b-catenin expression associated with disease progression in malignant melanoma. Br J Dermatol. 2001;145:210-216.
127. Arozarena I, Bischof H, Gilby D, et al. In melanoma, beta-catenin is a suppressor of invasion. Oncogene. 2011;30:4531-4543.
128. Nishizawa A, Nakanishi Y, Yoshimura K, et al. Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients. Cancer. 2005;103: 1693-1700.
129. Thies A, Schachner M, Berger J, et al. The developmentally regulated neural crest-Associated glycotope HNK-1 predicts metastasis in cutaneous malignant melanoma. J Pathol. 2004;203:933-939.
130. Vincent M, Thiery JP. A cell surface marker for neural crest and placodal cells: further evolution in peripheral and central nervous system. Dev Biol. 1984;103:468-481.
131. Giatromanolaki A, Sivridis E, Kouskoukis C, et al. Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res. 2003;13:493-501.
132. Korabiowska M, Cordon-Cardo C, Betke H, et al. GADD153 is an independent prognostic factor in melanoma: immunohistochemical and molecular genetic analysis. Histol Histopathol. 2002;17:805-811.
133. Hammock L, Cohen C, Carlson G, et al. Chromogenic in situ hybridization analysis of melastatin mRNA expression in melanomas from American Joint Committee on Cancer stage I and II patients with recurrent melanoma. J Cutan Pathol. 2006;33:599-607.
134. Duncan LM, Deeds J, Cronin FE, et al. Melastatin expression and prognosis in cutaneous malignant melanoma. J Clin Oncol. 2001;19: 568-576.
135. Deeds J, Cronin F, Duncan LM. Patterns of melastatin mRNA expression in melanocytic tumors. Hum Pathol. 2000;31:1346-1356.
136. Salti GI, Manougian T, Farolan M, et al. Microphthalmia transcription factor: a new prognostic marker in intermediate-Thickness cutaneous malignant melanoma. Cancer Res. 2000;60:5012-5016.
137. Robertson GP. Functional and therapeutic significance of Akt deregulation in malignant melanoma. Cancer Metastasis Rev. 2005;24:273-285.
138. Dai DL, Martinka M, Li G. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J Clin Oncol. 2005;23:1473-1482.
139. Rangel J, Nosrati M, Leong SP, et al. Novel role for RGS1 in melanoma progression. Am J Surg Pathol. 2008;32:1207-1212.
140. Zhang Z, Chen G, Cheng Y, et al. Prognostic significance of RUNX3 expression in human melanoma. Cancer. 2011;117:2719-2727.
141. Jonsson L, Bergman J, Nodin B, et al. Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: an analysis of 215 cases from the Malm Diet and Cancer Study. J Transl Med. 2011;9:114.
142. Hao H, Dong Y, Bowling MT, et al. E2F-1 induces melanoma cell apoptosis via PUMA up-regulation and Bax translocation. BMC Cancer. 2007;7:24-35.
143. Karst A, Dai DL, Martinka M, et al. PUMA expression is significantly reduced in human cutaneous melanomas. Oncogene. 2005;24:1111-1116.
144. Ladstein RG, Bachmann IM, Straume O, et al. Prognostic importance of the mitotic marker phosphohistone h3 in cutaneous nodular melanoma. J Invest Dermatol. 2012;132:1247-1252.
145. Safaee Ardekani G, Jafarnejad SM, Tan L, et al. The prognostic value of BRAF mutation in Colorectal cancer and melanoma: a systematic review and meta-Analysis. PLoS One. 2012;7:e47054.
146. Moreau S, Saiag P, Aegerter P, et al. Prognostic value of BRAF (V600) mutations in melanoma patients after resection of metastatic lymphnodes. Ann Surg Oncol. 2012;19:4314-4321.
147. Jakob JA, Bassett RL Jr, Ng CS, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012; 118:4014-4023.
148. Hoshimoto S, Kuo CT, Chong KK, et al. AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome. J Invest Dermatol. 2012;132:1689-1697.
149. Cesinaro AM, Sartori G, Migaldi M, et al. Prognostic significance of MGMT gene promoter methylation in differently treated metastatic melanomas. Pathology. 2012;44:313-317.
150. Winnepenninckx V, Lazar V, Michiels S, et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst. 2006;98:472-482.
151. Conway C, Mitra A, Jewell R, et al. Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival. Clin Cancer Res. 2009;15:6939-6946.
152. Kauffmann A, Rosselli F, Lazar V, et al. High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene. 2008;27:565-573.
153. Jewell R, Conway C, Mitra A, et al. Patterns of expression of DNA repair genes and relapse from melanoma. Clin Cancer Res. 2010;16: 5211-5221.